Testing a pill for skin conditions caused by keratin gene changes
Treatments studied
Part of Genetic & congenital, Skin clinical trials.
This study tests an oral medication called erlotinib (an EGFR inhibitor) to see if it can reduce the skin symptoms of keratinopathies like epidermolytic ichthyosis, epidermolytic palmoplantar keratoderma, and pachyonychia congenita. The goal is to improve skin condition and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed genetic diagnosis of a keratinopathy, such as epidermolytic ichthyosis, epidermolytic palmoplantar keratoderma, or pachyonychia congenita.
- Your skin symptoms must be moderate or severe in the areas being studied.
- You must be able to stop taking certain medications (like oral retinoids, steroids, or topical treatments) for a period before and during the study.
- You must be willing to have blood draws and skin biopsies for research.
- You cannot have active infections on the study skin areas, recent major surgery, or a history of invasive cancer in the past 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at “skin and blood biomarkers,” meaning measurable signs in the body, in people with ichthyosis to better understand the condition. It may help researchers find ways to track disease activity and evaluate future treatments.
This trial tests how a new drug works in people with actinic keratosis (rough, scaly patches caused by sun damage) on their upper arms or face. You will receive the treatment and have blood samples taken to see how your body processes the medication.
This study tests whether a daily pill called apremilast can reduce the number of new blisters in people with a genetic form of EBS (epidermolysis bullosa simplex). If you get more than 3 new blisters per day and have a confirmed KRT5 or KRT14 mutation, this trial may be a good fit.
This trial tests an experimental pill called soquelitinib for people with moderate to severe eczema (atopic dermatitis). It aims to see if the drug can reduce symptoms like itching and skin inflammation.
This study tests an investigational drug called HW211026 on actinic keratosis — rough, sun-damaged patches on the face. The goal is to see if this treatment can safely clear them up.
This Phase 2 study tests a topical cream (HT-001) to treat skin rashes caused by EGFR inhibitors. It aims to see whether the cream is safe and can reduce rash symptoms and discomfort.
Hear when a new Pachyonychia Congenita trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.